[HTML][HTML] Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Background Understanding the level and characteristics of protection from past SARS-CoV-
2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe …
2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe …
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Immunological memory is the basis of protective immunity provided by vaccines and
previous infections. Immunological memory can develop from multiple branches of the …
previous infections. Immunological memory can develop from multiple branches of the …
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
CP Arevalo, MJ Bolton, V Le Sage, N Ye, C Furey… - Science, 2022 - science.org
Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It
is difficult to create effective prepandemic vaccines because it is uncertain which influenza …
is difficult to create effective prepandemic vaccines because it is uncertain which influenza …
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
M Lipsitch, F Krammer, G Regev-Yochay… - Nature Reviews …, 2022 - nature.com
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
JS Tregoning, KE Flight, SL Higham, Z Wang… - Nature reviews …, 2021 - nature.com
Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
SARS-CoV-2 variants, vaccines, and host immunity
P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
[HTML][HTML] SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
S Pilz, V Theiler-Schwetz, C Trummer, R Krause… - Environmental …, 2022 - Elsevier
Seroprevalence surveys suggest that more than a third and possibly more than half of the
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …
Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination
that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of
currently licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses …
currently licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses …
The humoral response and antibodies against SARS-CoV-2 infection
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …